BMRN vs. MRNA: BioMarin Pharmaceutical vs. Moderna Stock Comparison
How do BioMarin Pharmaceutical (BMRN) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioMarin Pharmaceutical (BMRN) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BMRN | MRNA |
|---|---|---|
| Name | BioMarin Pharmaceutical Inc. | Moderna Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 10.85 billion USD | 101.48 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | July 26, 1999 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| Total Return (1Y) | 8.82% | 1,031.66% |
| Total Return (3Y, Annualized) | -12.54% | 58.68% |
| Total Return (5Y, Annualized) | -7.51% | 3.23% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| Volatility (1Y, Annualized) | 35.50% | 194.88% |
| Beta (5Y) | 0.24 | 1.08 |
| Max Drawdown (5Y) | -57.64% | -93.93% |
| Avg. Volume (3M) | 2.28M | 21.61M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| Sharpe Ratio (1Y) | 0.13 | 5.27 |
| Sortino Ratio (1Y) | 0.23 | 20.44 |
Profitability
ROE (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.31% and Moderna (MRNA) at -39.00% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.31%
- Max
- 109.18%
- Q3
- 6.23%
- BMRN
- -0.31%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BioMarin Pharmaceutical (BMRN) at -0.52% and Moderna (MRNA) at -141.43% report negative net margin values, usually indicating net losses over the period.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.52%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- BMRN
- -0.52%
- Q1
- -4.14%
- Min
- -17.05%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
Operating Margin (TTM)
Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioMarin Pharmaceutical (BMRN) reports 26.58%, ranking against industry peers normally.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.58%
- Max
- 83.12%
- BMRN
- 26.58%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
Profitability Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| ROE (TTM) | -0.31% | -39.00% |
| ROA (TTM) | 3.89% | -13.26% |
| Net Margin (TTM) | -0.52% | -141.43% |
| Operating Margin (TTM) | 26.58% | -557.93% |
| Gross Margin (TTM) | 53.21% | -66.02% |
Growth
Revenue Growth
BioMarin Pharmaceutical (BMRN) at 12.87% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Only one side can be read here: BioMarin Pharmaceutical (BMRN) reports EPS growth of -18.55%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.
Growth Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| Revenue Growth (YoY) | 12.87% | -39.92% |
| Revenue Growth (3Y CAGR) | 15.40% | -53.30% |
| EPS Growth (YoY) | -18.55% | -- |
| EPS Growth (3Y CAGR) | 33.89% | -- |
Financial Strength
Current Ratio (MRQ)
Both BioMarin Pharmaceutical (BMRN) at 2.44 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.44
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BMRN
- 2.44
- Min
- 0.10
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
Debt / Equity (MRQ)
Moderna (MRNA) at 0.19 carries an industry-typical debt-to-equity mix, while BioMarin Pharmaceutical (BMRN) at 0.67 uses more debt funding than most peers.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.67
- Max
- 1.42
- BMRN
- 0.67
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 2.44 | 2.30 |
| Debt / Equity (MRQ) | 0.67 | 0.19 |
| Net Debt / EBITDA | 4.04 | -- |
Dividends
Dividend Yield (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BMRN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioMarin Pharmaceutical (BMRN) nor Moderna (MRNA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BMRN
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
P/S Ratio (TTM)
BioMarin Pharmaceutical (BMRN) at 2.97 looks cheap on sales in the lower P/S ratio quartile, while Moderna (MRNA) at 45.55 looks rich in the upper quartile — a clear gap in price per dollar of revenue.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.97
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- BMRN
- 2.97
- Min
- 0.01
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioMarin Pharmaceutical (BMRN) at 1.73 is valued about in line with its industry on P/B ratio, while Moderna (MRNA) at 11.58 carries an above-peer premium to book — MRNA is pricier on assets.
BMRN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.73
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- BMRN
- 1.73
- Q1
- 1.69
- Min
- -5.59
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BMRN | MRNA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 2.97 | 45.55 |
| P/B Ratio (MRQ) | 1.73 | 11.58 |
| Free Cash Flow Yield (TTM) | -0.15% | 0.29% |